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Introduction
Primary hyperparathyroidism (PHPT) occurs as a result
of unregulated over-production of parathyroid
hormone (PTH) secreted from the parathyroid glands,
leading to an inappropriate calcium homeostasis. PHPT
per se is considered a rare disease with a variable
prevalence; but data from the Rochester
Epidemiological Project reported the incidence of
PHPT as 21.6 cases per 100,000 person-years.1
Approximately 90% of patients with PHPT have
significantly high serum PTH concentrations, while 10-
20% may have only minimally elevated PTH levels.2 The
commonest underlying aetiology is a solitary
adenoma, accounting for almost 80-85% of the cases,
whereas multi-glandular disease has been reported in
5% of patients with PHPT.3 Hyperplasia of parathyroid
gland and carcinoma are less frequently seen, with a
reported prevalence of < 1% of parathyroid carcinoma
among patients with PHPT.4,5
The clinical features that accrue are largely related to
circulating PTH levels and the ensuing degree of
hypercalcaemia. Women are affected more often than
men, with a peak incidence between 50 and 60 years of
age, and skeletal and renal manifestations being the
commonest. However, the trend of symptomatology has
changed in countries, with well-developed health care
services, due to early diagnosis made possible by routine
biochemical screening.6 A higher incidence of
symptomatic disease is seen in patients with PHPT in
countries with poor resources for health care. Surgical
treatment is generally a well-tolerated approach to cure,
and is the mainstay of long-term disease free survival.
The current study was planned to report the diverse
clinical presentations, causes and the outcome of
treatment of PHPT.
Patients and Methods
This observational, retrospective study was conducted
at the Endocrine Unit of Jinnah Postgraduate Medical
Centre (JPMC), Karachi, and comprised records of
patients with diagnosis of hyperparathyroidism from
2004 to 2014.
PHPT was diagnosed on the basis of high or normal
ionised calcium levels with high or inappropriate
serum PTH levels. Clinical presentation, laboratory
parameters, imaging, histology and surgical outcome
were studied.
Data was analysed using SPSS 17. For descriptive statistics
like gender, co-morbidities, presenting clinical features,
histology and tumour location, frequency and
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percentages were calculated, while means were
calculated for age, duration of disease, pre-operative and
post-operative biochemical parameters, like serum PTH,
calcium (Ca), phosphate (PO4) and alkaline phosphatase
(AlkPO4).
Results
Of the 25 participants, 24(96%) were females and 1(4%)
was male. The overall mean age was 41.72±15.9 years.
The commonest affected age group lay between 21-40
years with 11(44%) patients compared to 8(32%)
patients aged between 41-60 years, 4(16%) patients
aged above 60 years and 2(8%) patients aged below 20
years. Mean values for serum Ca, PO4 and AlkPO4 were
11.23±1.6, 2.4±0.83 and 673.5±729.6, respectively
(Table).
Patients were divided into three groups based on the
serum Ca level, i.e.7 (28%)
normocalcaemic patients (serum Ca =
8.5-10.5 mg/dl), 17(68%)
hypercalcaemic patients (serum Ca>
10.5 mg/dl), and 1(4.0%)
hypocalcaemic patient (serum Ca<
8.5 mg/dl). Comparison of calcium
status to the PTH level revealed that
patients with normocalcaemia had
lower PTH levels than those with
hypercalcaemia (Figure-1). However,
the 1(4%) patient with hypocalcaemia
had markedly elevated PTH level.
Moreover, 23(92%) patients had
vitamin D deficiency.
Patients had varied clinical
manifestations, bone disease
being the primary presentation in 17(68%) patients,
whereas 4(16%) had recurrent stone disease; 1(4%)
patient presented with chronic headache and 2(8%)
patients reported with acute abdomen, of which one
had acute pancreatitis and the other had severe
abdominal pain due to hypercalcaemia and
cholelithiasis (Figure-2).
Patients with bone disease had variable clinical
presentations, body aches and fatigue being the
commonest manifestation in 11(44%), followed by
inability to walk with fractures in 3(12%) patients, who
also had a prior history suggestive of proximal
myopathy. Jaw mass was seen in 3(12%) patients. Only
1(4%) patient had asymptomatic hypercalcaemia and
was detected on routine biochemical screening. The
patient with history of chronic headache and
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Table: Baseline biochemistry and hormone levels.
Normal Range Means ± SD Range (Min-Max)
Serum Ca 8.1-10.4 mg/dl 11.23±1.6 7.3-14.4
Serum PO4 2.5-4.8 mg/dl 2.4±0.83 1.03-4.2
Serum AlkPO4 65-360 U/L 673.5±729.6 55-2335
Serum intact PTH (Pre-operative) 16-81 pg/ml 879.47±793.5 79.1-2500
Median – 518.0
Serum Intact PTH (Post operative) 16-81 pg/ml 246.45±387.9 11.3-1398.0
Median – 61.0
Serum Cr 0.5-1.2 mg/dl 1.05±0.64 0.30-3.2







PTH: Parathyroid hormone. PHTP: Primary hyperparathyroidism
Figure-1: Relation between calcium status and PTH level of patients with PHPT.
uncontrolled hypertension had parathyroid adenoma in
the context of multiple endocrine neoplasia type
2A(MEN-2A), with histologically proven bilateral
pheochromocytoma, medullary carcinoma of thyroid
and parathyroid adenoma.
Histology of the jaw mass was consistent with brown
tumour in 2(8%) patients, and giant cell granuloma of
mandible in 1(4%) patient. X-rays were only done for
patients with focal bone-related symptoms. Of the
patients with jawmass, an osteoclastic lesion was evident
in mandibular rami in 2(66.7%) of them and 1(33.3%) had
intra-oral soft tissue swelling. The patients with inability
to walk had severe generalised osteopenia with
pathological fractures in pubic rami, greater trochanter
and neck of femur.
Comparison of serum calcium level with disease
manifestations revealed that all patients with stone
disease had hypercalcaemia while 10(58.8%) of the
hypercalcaemic patients had hypercalcaemia in bone
disease group. Hypertension was recorded in 6(24%)
patients, 1(4%) patient had concomitant diabetes and
1(4%) had hypothyroidism. Median lag time from
symptom onset to diagnosis of PHPT was 3 years, with a
mean duration of clinical symptoms of 4.1±3.3 years.
Ultrasonography of neck was normal in 12(48%) patients
and was not done in 3(12%) patients. It showed
hypoechoic lesion near the inferior pole of thyroid in
10(40%) patients. Sestamibi scan was positive for a
functioning parathyroid
adenoma in 17(68%) patients. Of
the 8(40%) patients who had
negative myocardial perfusion
(MIBI) scan, 1(12.5%) had ectopic
parathyroid located in the
mediastinum, which was
detected onmagnetic resonance
imaging (MRI). A total of 21(84%)
patients had parathyroid
adenoma at usual anatomical
site while 4(16%) had an ectopic
location.
All patients underwent excision
of involved gland where pre-
operative localisation was
available, while for un-localised
cases bilateral neck exploration
was performed. The 1(4%)
patient with ectopic parathyroid
had median sternotomy. The
patient with MEN-2A had total
thyroidectomy with
parathyroidectomy and bilateral adrenalectomy.
Histology revealed a single adenoma in 23(92%) patients,
carcinoma in 1(4%), and 1(4%) patient had adenoma of
one gland with hyperplasia in the remaining parathyroid
glands.
Post-operative PTH levels were normalised in 15(60%)
patients, within the first 2 weeks after surgery, while mild
short-term or recurrent PTH elevation was observed in
6(24%) patients. No post-operative PTH level and bone
biochemistry was available for 4(16.0%) patients due to
irregular follow-up visits.
Discussion
A striking discrepancy exists with respect to incidence,
clinical manifestations and complications of PHPT across
the globe. The current study was a small but systematic
study to collate the estimates of diverse clinical spectrum
of PHPT in our patients, keeping in mind the delay in
diagnosis. This may help clinicians in better
understanding the variable presentations of PHPT and
hence early diagnosis. It may also help to delineate the
underlying mechanisms for such varied clinical
manifestations. As yet unknown, environmental and
nutritional factors may also influence the incidence of
disease. Sparse documentation is available regarding the
exact prevalence of hyperparathyroidism in Pakistan. Very
few studies pertaining to PHPT have been reported from
Pakistan.7,8
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PHTP: Primary hyperparathyroidism.
Figure-2: Clinical manifestations of patients with PHPT.
There are wide variations in the clinical spectrum of PHPT
in our geographical region. Here, it involves considerably
younger age group, with symptomatic
hyperparathyroidism; hence recurrent calculi and overt
bone disease are still the predominant forms of the
disease. Crippling skeletal manifestations mainly account
for the morbidity associated with the disease. Most of our
patients had some form of skeletal disease, indicating a
substantial delay in diagnosis. Other studies from our
region have also reported a higher prevalence of bone
disease (30-46%) and stone disease (20-30%) in patients
with PHPT.8-10 A recent study from India has also reported
a higher prevalence of bone disease and proximal
myopathy (60%).11 Similarly, a study from Iran reported
bone disease in 60-100% patients, in the form of bone
pain, fractures or osteitisfibrosa cystica.12 Our findings are
similar to those from other Eastern countries, in terms of
the clinical and biochemical features of PHPT. However,
this is in contrast to the developed nations where
symptomatic disease has become an exception rather
than the rule. Our contemporary data has similarities to
the western historic presentation of PTHP. It is important
to note that renal disease is still considerably less
compared to the past Western data. This may be due to
less significant hypercalcaemia in our cohort. Only one
patient was male in our study, reflecting the unexplained
predominance of this disease in females, also reported in
other studies.7-13
The routine evaluation of serum biochemistry in the
developed countries has led to the origin of a new entity,
'asymptomatic normocalcaemic hyperparathyroidism',
thus representing a change in the clinical spectrum of
hyperparathyroidism.14-16 A population-based survey
conducted in Sweden reported a 0.6% prevalence of
normocalcaemic PHPT in postmenopausal women,
while a study from Saudi Arabia reported asymptomatic
PHPT in 23.9% of their study cohort.17,18 However, even
in normocalcaemic PHPT, a higher prevalence of
urolithiasis has also been reported.19 Although many of
our patients had normocalcaemia, none of them were
asymptomatic. Normocalcaemia can be attributed to
concomitant vitamin D deficiency, as our population has
a high prevalence of vitamin D deficiency/insufficiency.
A study from Lahore, Pakistan, has also reported
normocalcaemia in 21.88% of patients with
hyperparathyroidism.8 Studies from other parts of the
world have reported 11-13% of the patients with acute
severe pancreatitis in the context of PHPT, whereas our
cohort only had one patient presenting in this
manner.20,21
It is quite difficult to determine the vitamin D level below
which PTH hypersecretion starts. It is even more difficult
to decide in normocalcaemic patients with
hyperparathyroidism, as to whether the PTH
hypersecretion is due to autonomous stimuli or a positive
feedback due to long-standing low vitamin D3 levels. In
addition, the high circulating plasma PTH levels decrease
plasma 25-hydroxy vitamin D levels (25-OHD), due to an
increased metabolic clearance of 25-OHD via increased
faecal excretion of vitamin D-derived products. The
association between hypersecretion of PTH in PHPT
patients, with hypovitaminosis D causing
normocalcaemic PHPT, has opened new possibilities for
regional differences in the clinical manifestations of PHPT,
which is linked to the prevalence of vitamin D3 deficiency
in the general population of that region. Due to the
significant prevalence of vitamin D
deficiency/insufficiency in individuals with PHPT, it is
desirable to measure vitamin D3 in all these patients and
treating those with low levels, prior to making any
management decisions regarding hyperparathyroidism. It
has been reported that a 25-OHD threshold of >50 nmol/L
(i.e. 20ng/ml) is sufficient for prevention of secondary
hyperparathyroidism in persons with normal renal
function.22
Parathyroid glands are known to vary in anatomic
location, and typical ectopic sites include intra-
thyroidal, lateral neck and mediastinum. An ectopic
location of parathyroid adenoma is a very rare cause of
hyperparathyroidism, reported in 1-2% of all cases. A
study from Pakistan reported three cases with ectopic
parathyroid location among 70 patients operated for
PHPT over a 20-year period.23 However, 4 cases of PHPT
with ectopic adenoma were encountered in this small
cohort of patients. The ectopic location of parathyroid
adenoma is recognised as an important cause of
persistent PTH elevation due to failed neck exploration
surgery, especially in cases with equivocal/failure to
localise through all pre-operative modalities. An Indian
study has reported 7 ectopic parathyroid adenomas
out of 51 cases operated for PHPT.24 One patient with
jaw mass had a giant cell granuloma, which is rarely
seen as a sole manifestation of PHPT. Very few cases
have been reported, where a prior diagnosis of
peripheral giant cell granuloma has led to the
identification of PHPT subsequently.25-27 Brown
tumours can present as giant cell reparative lesions,
therefore if any patient presents with a suspicious
intraoral lesion, either soft tissue mass or involvement
of jaw bone, it is mandatory to keenly investigate for
PHPT by all possible means. A significant proportion of
patients develop PHPT as a part of MEN syndrome.28
MEN-related hypercalcaemia and parathyroid hormone
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levels are comparatively lower than sporadic PHPT.29,30
Though the demographic and biochemical features of
our patient with MEN-2A closely resemble those
reported in literature, due to the paucity of data on
MEN-2A as well as PHPT from our region, it is difficult to
portray the clinical pattern of PHPT in context of MEN
syndrome.
Various non-invasive imaging tools for localising PHPT
are available, however, Technetium (TC-99m) sestamibi
is the most authentic and widely used modality.
Accurate localisation was achieved in 65.2% of our
patients. However, it has been suggested that the
uptake of MIBI in hyper-functioning parathyroid is
dependent on gland size and the amount of cellular
components. Studies have also reported the overall
true-positive cases for sestamibiscans at 56% to 87%;
the positivity being related in part to the adenoma size
and pre-operative ionised calcium level.31,32 A negative
MIBI scan has been reported in 50% of cystic and 27.7%
of solid parathyroid adenomas with an overall Tc MIBI
scan efficacy of 67%.33 It has been postulated that MIBI
uptake is reduced in the presence of uraemia, and one
of our patients with negative sestamibi scan also had
chronic kidney disease, which evolved over the course
of uncontrolled hyperparathyroidism. This was the only
patient with hypocalcaemia despite markedly elevated
PTH levels, as a result of low bone reserve on account of
severe complex bone disease.
Although patients with more severe disease, as
manifested by severe hypercalcaemia, may have an
increased risk of death, the overall survival is not
adversely affected among patients with mild degree of
PHPT.34 The severe form of disease seen in this study may
in part be related to the delay in seekingmedical care due
to lack of awareness and paucity of adequate health care
facilities for low socio-economic group patients in this
country.
Conclusion
A high index of suspicion is required for clinching the
early diagnosis of primary hyperparathyroidism.
Concomitant vitamin D deficiency masks the
hypercalcaemia, related to elevated PTH levels, thus
leading to a delay in diagnosis. Therefore, hypercalcaemia
must not be used alone as a screening tool for PHPT. In
addition, long-standing vitamin D deficiency may cause
hyperplasia/and or adenoma of parathyroid glands due to
PTH dysregulation.
Disclaimer: None.
Conflict of Interest: None.
Source of Funding: None.
References
1. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant
CS, et al. Incidence of primary hyperparathyroidism in Rochester,
Minnesota, 1993-2001: an update on the changing epidemiology
of the disease. J Bone Miner Res 2006; 21: 171-7.
2. Nussbaum S. Immunometric assays of parathyrin in the diagnosis
of hypercalcemic individuals. Clin Chem 1991; 37: 142-3.
3. Molinari AS, Irvin GL, Deriso GT, Bott L. Incidence of
multiglandular disease in primary hyperparathyroidism
determined by parathyroid hormone secretion. Surgery 1996;
120: 934-7.
4. Givi B, Shah JP. Parathyroid Carcinoma. Clin Oncol 2010; 22:
498-507.
5. Rawat N, Khetan N,Williams DW, Baxte JN. Parathyroid carcinoma.
Br J Surg 2005; 92: 1345-53.
6. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic
primary hyperparathyroidism. N Engl J Med 2004; 350: 1746-51.
7. Biyabani SR, Talati J. Bone and renal stone disease in patients
operated for primary hyperparathyroidism in Pakistan: Is the
pattern of disease different from west? J Pak Med Assoc 1999; 49:
194-8.
8. Afzal A, Gauhar TM, Butt WT, Khawaja AA, Azim KM. Management
of hyperparathyroidism: A five year surgical experience. J Pak Med
Assoc 2011; 61: 1194-8.
9. Bhansali A, Masooodi SR, Reddy KS, Behera A, das Radotra B, Mittal
BR, et al. Primary hyperparathyroidism in north India: a
description of 52 cases. Ann Saudi Med 2005; 25: 29-35.
10. Gopal A, Acharya SV, Bandgar T, Menon PS, Dalvi AN, Shah NS.
Clinical profile of primary hyperparathyroidism from western
India: a single centre experience. J Postgrad Med 2010; 56: 79-84.
11. Jha S, Jayaraman M, Jha A, Jha R, Modi KD, Kelwadee JV. Primary
Hyperparathyroidism: A changing scenario in India. Indian J
Endocrinol Metab 2016; 20: 80-3.
12. Bahrami A. Primary hyperparathyroidism in Iran: a review. Int J
Endocrinol Metab 2008; 1: 50-7.
13. Mazeh H, Sipple RS, Chen S. The role of gender in primary
hyperparathyroidism: same disease, different presentation. Ann
Surg Oncol 2012; 19: 2958-62.
14. Marques TF, Vasconcelos R, Diniz E, Rêgo D, Griz L, Bandeira F.
Normocalcemic primary hyperparathyroidism in clinical practice:
an indolent condition or a silent threat? Arq Bras Endocrinol
Metabol 2011; 55: 314-7.
15. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ.
Normocalcemic primary hyperparathyroidism: further
characterization of a new clinical phenotype. J Clin Endocrinol
Metab 2007; 92: 3001-5.
16. Bilezikian, JP, Silverberg SJ. Normocalcemic primary
hyperparathyroidism. Arq Bras EndocrinolMetabol 2010; 54: 106-9.
17. Lundgren E, Rastad J, Thurfjell E, Åkerström G, Ljunghall S.
Population-based screening for primary hyperparathyroidism
with serum calcium and parathyroid hormone values in
menopausal women. Surgery 1997; 121: 287-94.
18. Malabu UH, Founda MA. Primary hyperparathyroidism in Saudi
Arabia: A review of 46 cases. Med J Malaysia 2007; 65: 394-7.
19. Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F.
Normocalcemic versus Hypercalcemic Primary
Hyperparathyroidism:More Stone than Bone? J Osteoporosis; 2012.
20. Jacob JJ, John M, Thomas N, Chacko A, Cherian R, Selvan B, et al.
Does hyperparathyroidism cause pancreatitis? A South Indian
experience and a review of published work. ANZ J Surg 2006; 76:
740-4.
21. Carnaille B, Oudar C, Pattou F, Combemale F, Rocha J, Proye C.
Pancreatitis and primary hyperparathyroidism: forty cases. Aust N
Vol. 67, No. 4, April 2017
The many guises of primary hyperparathyroidism…An unchanged scenario 584
Z J Surg 1998; 68: 117-9.
22. SalibaW, Barnett O, Rennert HS, Lavi I, Rennert G. The relationship
between serum 25(OH)D and parathyroid hormone levels. Am J
Med 2011; 124: 1165-70.
23. Abbas F, Biyabani SR, Memon A, Talati J. Mediastinal parathyroid
adenoma causing Primary hyperparathyroidism. J Pak Med Assoc
2007; 57: 93-5.
24. Muthukrishnan J, Jha S, Modi KD, Jha R, Kumar J, Verma A, et al.
Symptomatic primary hyperparathyroidism: a retrospective
analysis of fifty one cases from a single centre. J Assoc Physicians
India 2008; 56: 503-7.
25. Smith BR, Fowler CB, Svane TJ. Primary hyperparathyroidism
presenting as a "peripheral" giant cell granulomas. J Oral
Maxillofac Surg 1988; 46: 65-9.
26. Aswath N, Chidambaranathan P. Primary hyperparathyroidism as
a central giant cell granuloma of the jaws: pre and post operative
treatment pattern of clinical and radiographic presentations. IJCRI
2012; 3: 51-6.
27. Gataa IS, Zardawi FM. Primary hyperparathyroidism presented as
central giant cell granuloma of jaw bones. A report of three cases.
IOSR J Dent Med Sci 2015; 14: 75-9.
28. Moline J, Eng C. Multiple endocrine neoplasia: an overview. Genet
Med 2011; 13: 755-64.
29. Twigt BA, Scholten A, Valk DG, Rinkes-Borel IHM, Vriens MR.
Difference between sporadic and MEN related primary
hyperparathyroidism; clinical expression, preoperative work-up,
operative strategy and follow-up. Orphanet J Rare Dis 2013; 8: 50.
30. Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, et al.
Primary hyperparathyroidism in multiple endocrine neoplasia
type 2A. J Intern Med 1995; 238: 369-73.
31. Swanson TW, Chan SK, Jones SJ, Bugis S, Irvine R, Belzberg A, et al.
Determinants of Tc-99m sestamibi SPECT scan sensitivity in
primary hyperparathyroidism. Am J Surg 2010; 199: 614-20.
32. Moka D, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H.
Technetium 99m-MIBI-SPECT: A highly sensitive diagnostic
tool for localization of parathyroid adenomas. Surgery 2000;
128: 29-35.
33. Ghasemi-Rad M, Lesha e, Abkhiz S, Mohammadi A. Primary
Hyperparathyroidism: Comparing between solid and cystic
adenomas and the efficacy of ultrasound and single-photon
emission computed tomography in their diagnosis. Endocr Prac
2015; 21: 1277-81.
34. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon
WM, et al. Survival after the diagnosis of hyperparathyroidism: a
population-based study. Am J Med 1998; 104: 115-22.
J Pak Med Assoc
585 T. Ahsan, U. Erum, K. M. I. Pal, et al
